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Executive Summary

From May 3-12, 1994, the Population Council, in conjunction with the
Pacific Institute for Women's Health and the International Women's Health
Coalition, hosted a meeting for women's health advocates from around the world
to discuss the development of microbicides. Microbicides are pharmaceutical
products that have the potential to prevent the transmission of HIV and other
sexually transmitted infections when applied intravaginally. The group spent six
working days in New York and two in Washington, DC and met with a wide
range of scientists involved in microbicide research and development. We also
met with senior staff from the U.S. Agency for International Development
(USAID), the U.S. Food and Drug Administration (FDA), and the National
Institutes of Health (NIH), as well as with women's congressional and lobbying
groups. It was an intensive eight-day consultation and, although the itinerary
was quite full, the women met frequently as a small group and discussed their
emerging concerns and impressions. This process was the first step in building
greater understanding and mutual respect among women's health advocates
and Population Council staff and scientists in regard to the technology of
microbicides. It is hoped that the recommendations resulting from this initiative
will have a positive influence not only on the development of microbicides, but on
all reproductive health technologies.
In producing a report of this consultative process, we decided as a group
that rather than an exhaustive summary of our discussions, we would aim to
reproduce some of the flavor of our deliberations by compiling short essays from
most of the meeting participants. We felt that this format -- by allowing
participants an opportunity to speak in their own voice -- would best capture the
exploratory and often inconclusive nature of our initial discussions. The
complexities of AIDS and its prevention belie the possibility of simple definitive
recommendations, hence our emphasis on an on-going process of consultation
and partnership.
As a group, we would like to acknowledge the considerable effort
expended by Jennifer Grant in compiling and editing our individual contributions
to this report. Jennifer also wrote the text that weaves the various pieces
together into a coherent story.

Background to the Meeting
Christiana Coggins
Programs Division
The Population Council

The Population Council, the Pacific Institute for Women's Health, and the
International Women's Health Coalition share a commitment to women's
reproductive health. In recent years, these institutions have called attention to
women's exposure to reproductive tract infections (RTIs), including sexually
transmitted diseases (STDs) and AIDS, within the broader context of
reproductive and sexual health and cultural realities. Recognizing women's risk
of infection points to an urgent need both to address the sociocultural aspects of
women's sexual health and to develop woman-controlled prevention methods
that will provide protection against sexually transmitted infection. Our three
organizations, therefore, collaborated in May 1994 to initiate an ongoing
consultative process between women's health advocates and scientists with
regard to the technology of vaginal microbicides.
The term "vaginal microbicide" refers to any compound capable, when
applied intravaginally, of preventing the transmission of sexually transmitted
pathogens -- including bacteria, parasites, and/or viruses, such as HIV. Ideally,
microbicidal products would be formulated and distributed in such a way as to
ensure that they are truly woman-controlled and neither provider nor partner
dependent. This advance would give women a tool they urgently want. The
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PC/PI/IWHC initiative is committed to the timely development of safe and
effective "microbicides" -- as opposed to the more narrow concept of a "virucide"
-- because women require protection against the full range of sexually
transmitted infections. Indeed, at present in many parts of the world these more
common reproductive tract infections are responsible for greater amounts of
morbidity and mortality than HIV/AIDS.
While the development of a microbicide is of critical importance, this
technology alone will not redress the underlying conditions of women's lives that
make them vulnerable to sexually transmitted disease. The global strategy to
prevent STDs and AIDS has so far encouraged people to reduce their number of
sexual partners and to use condoms. These strategies, however, most often do
not confront the power imbalances that exist between men and women that
make it virtually impossible for some women to refuse unwanted or unprotected
sex. Gender power inequity also shapes the economic realities that necessitate
the selling of sex by women and girls and the social perceptions that stigmatize
women who use STD services.
The May meeting was designed to prepare participants for sophisticated
debate on microbicide research, development, and introduction by reviewing
detailed background information on science and policy issues; to consolidate a
vision of the groups's collective goals over the next five-plus years; to expose
Population Council staff and management to first-hand accounts of women's
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views and concerns; to introduce participants to the politics, institutions and
personalities that will shape the direction of microbicide development over the
next five to ten years; and to develop a tentative three-year plan of action and
funding proposal to support the future work of the consultative group.

These activities supported the general goals of the meeting, which were to:
•

ensure that the Population Council's current commitment to microbicide
development results in the availability of vaginal products that are safe,
effective, and meets women's needs;

•

develop a model for future reproductive health technology development
that engages women as active partners in all aspects of the product
development process;

•

further dialogue between women's health advocates, scientists, and program
planners on issues that affect women's sexual and reproductive lives,
especially with respect to STD and HIV prevention;

•

increase the ability of women to serve as effective advocates by increasing
their understanding of and access to scientific information and to the institut
ions and decision makers that affect policy; and

•

foster sensitivity and insight among scientists regarding the realities of
women's lives that influence the introduction, safety, and effective use of
reproductive health technologies, especially those seeking to prevent
sexually transmitted infection.

The ideas, opinions and recommendations that emerged from the meeting
will be instrumental in the Population Council's efforts to incorporate a women's
health perspective into the range of activities that constitute new product
development -- from formulation of products in the laboratory, through design of

3

study protocols, to the actual implementation of field research. This meeting was
but the first step in building greater understanding and mutual trust and respect
among women's health advocates and the Population Council's program
planners and scientists. We hope that the changes resulting from this initiative
will ultimately affect all future reproductive health technology development.
To achieve a balance of perspectives, similar numbers of women's health
advocates, program planners, and scientists were asked to participate.
Advocates from Latin America, Africa, Asia, Western Europe and the United
States were invited to the consultation. The nucleus of the meeting was
comprised of nine international women's health advocates and nine staff and
scientists from the Pacific Institute, IWHC, and the Population Council's
Programs Division and Center for Biomedical Research. A full agenda of our
eight day consultation is attached, along with a complete list of participants. In
planning the meeting we arranged for the group to spend six working days in
New York and two in Washington, DC and to meet with a wide range of
scientists involved in microbicide research and development. We also scheduled
meetings with senior staff from the U.S. Agency for International Development
(USAID), the U.S. Food and Drug Administration (FDA), and the National
Institutes of Health (NIH), as well as with women's congressional and lobbying
groups. Toward the end of the consultation the women's health advocates
presented their concerns and recommendations to the senior staff of the
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Population Council for consideration and discussion. These recommendations
are attached to this report and have formed the basis for interim action on behalf
of the Population Council. Progress on these recommendations will be
discussed at the next meeting of the group, which is to be hosted by the Pacific
Institute for Women's Health in Washington, DC in October, 1994.
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Partnership for Prevention

In her opening comments, Adrienne Germain (Vice-president,
International Women's Health Coalition) called the consultation an historic event
because it was one of the first efforts to bring together scientists, program
planners, and women's health advocates to debate issues related to an
important new reproductive health technology at an early stage in its
development. Several years ago, the International Women's Health Coalition
together with the World Health Organization sponsored a two-day dialogue
concerning the need for earlier and more intensive exchange between scientists
and advocates in the development of contraceptive technology. These
discussions were summarized in their publication entitled Creating Common
Ground. The May consultation was an excellent example of the type of early
dialogue recommended by that report.
Historically, the Population Council has focused on the development of
long-acting methods of contraception, as Christopher Elias (Senior Associate,
Population Council) explained in his overview of the organization's work in
technology development. For example, the Council was primarily responsible for
development of the Copper T IUD and NORPLANT® subdermal implant system.
Several years ago, however, David Phillips (Senior Scientist, Center for
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Biomedical Research) and colleagues began to conduct experiments aimed at
elucidating the precise mechanism of the sexual transmission of HIV across
mucosal membranes. As an outgrowth of this work, several cell culture systems
were developed for screening potentially microbicidal compounds, suggesting
the possibility of developing a vaginal product capable of preventing HIV and
other sexually transmitted infections.
Two and a half years ago, at the invitation of George Zeidenstein, then
president of the Population Council, David and Chris made a joint presentation to
the Population Council's Board of Trustees. They asserted that the expanding
epidemic of sexually transmitted diseases (STDs) and AIDS mandated greater
Council involvement in the development of barrier contraceptive methods, and
suggested that vaginal formulations of products that women could use to protect
themselves from STDs should be a priority for the Council's development
program. They specifically requested and received the Board's permission to
pursue both contraceptive and noncontraceptive microbicidal preparations,
arguing that the latter are essential for promoting safe fertility choice among all
women at risk of sexually transmitted infection. Subsequent to that approval, the
Center for Biomedical Research and Programs Division have developed and
implemented a detailed workplan that includes continuing basic research, as well
as pursuing a critical path of microbicidal product development. This
interdivisional collaboration has resulted in significant advances. Several
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formulations of microbicidal compounds are now in the preclinical stage of
product evaluation and we anticipate beginning clinical testing of at least one of
these products by the end of 1994. This progress has also been reflected in an
exponential rise in the commitment of staff and financial resources to microbicide
development within the Council over the past three years.
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Developing HIV Prevention Technologies for Women: The Need for Partnership
David M. Phillips, Senior Scientist
Center for Biomedical Research
The Population Council

The specific mandate of the Council's Center for Biomedical Research
(CBR) is to carry out research that will serve as underpinnings for advances in
the area of women's reproductive health. Traditionally CBR has focused on
contraceptive development, but recently -- in the face of the growing need -- we
have expanded into developing new ways for women to protect themselves
against STDs, especially HIV/AIDS. At this juncture, it is important to identify
mechanisms for receiving input from women who will be most affected by the
development of microbicides.
Most of my own research on microbicides is still in a preclinical stage.
When we began our work on HIV six years ago, it was generally believed that
sexual transmission was initiated by the entrance of free-virus particles into tiny
lesions in the epithelial cells that line the genital tract. Using cervix-derived cells
that were grown in the laboratory, we demonstrated that HIV-infected white
blood cells in genital tract secretions, or blood, are probably the vectors for HIV
transmission. We have observed that infection is initiated by adhesion of these
white blood cells to intact epithelia which line the genital tract. The laboratory
cell cultures and assay systems that we developed to carry out this basic
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research, have allowed us to identify several compounds that seem to block HIV
infection of epithelial cells from the female genital tract. We have also found that
the same compounds may inhibit chlamydial infection.
The Partnership for Prevention consultation confirmed for me that we are
now at the stage where we need the advice of women "in the field" to determine
how best to find out, 1) whether women are receptive to the use of such
formulations, 2) whether other types of formulations may be better suited to their
needs and lifestyles, 3) whether vaginal formulations containing such
compounds can prevent the transmission of HIV and other sexually transmitted
pathogens during the conditions of sexual intercourse in real-life situations, and
4) how to proceed with testing such formulations so as to learn how they can,
and should, be introduced and used.
All research at the Population Council must be carried out with special
understanding of the long-term effects that women might encounter when the
product is put into use as well as the short-term effects on women involved in
clinical trials. In my opinion, it is in this area that productive interaction with
women's health advocates can be most helpful. The role of such advocates is
especially critical in light of the great gulf that separates biomedical scientists of
the western world from women of the developing world. Our interaction has
great potential to be mutually beneficial: scientists will learn how best to test and
deliver a new reproductive health product that is both safe and effective and
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meets women's needs and women's health advocates will be provided with
access to accurate scientific information to inform and propel the advocacy
process. Along the way we all stand to gain from the development of mutual
respect and the possibility of establishing partnership where, too often, there has
been adversity.
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In 1992, the Council's Ebert Program on Critical Issues in Reproductive
Health and Population decided to hold a seminar on microbicide development as
a means of developing consensus within the scientific community regarding the
need for and feasibility of developing such woman-controlled prevention
technology. Lori Heise (Director, Pacific Institute for Women's Health,
Washington, DC) worked with Chris Elias to organize a one day seminar in June
1992. Women's health advocates, scientists, and program planners were invited
to discuss a range of issues including the need for a female-controlled
microbicide and how such a product would fit into broader AIDS prevention
strategies. Later that year, Chris and Lori wrote The Development of
Microbicides: A New Method of HIV Prevention for Women which was printed in
1993 as a Population Council Working Paper. As a joint production of a scientist
and an advocate, this working paper provided an explicitly feminist analysis of
the need for microbicide development, as well as a pragmatic review of the
principal challenges to be faced in advancing the development of safe, effective,
and affordable microbicidal products.
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What Women Need in an HIV Prevention Method
Lori Heise
Director
The Pacific Institute for Women's Health, Washington DC

I came to the issue of microbicide research through my work on sexuality
and violence against women. As I listened to women and to the frustrations of
HIV prevention workers, it became increasingly clear that condoms simply were
not an option for many women. Women told stories of being abandoned,
ridiculed, or beaten for raising the issue of condom use with their partners.
Others were afraid even to ask. It wasn't always violence they feared, however,
but also the prospect of losing a relationship that was emotionally and/or
economically important to them.
The AIDS mantra, "Always use a condom," seemed to ignore their
realities and asked women to protect themselves by using a technology outside
of their control. It also seemed particularly insensitive that the only option
women had to protect themselves was one that also prevents pregnancy while,
in many cultures, a woman's social status depends on her ability to bear children.

Given these dilemmas, I formulated a simple question and took it to every
AIDS expert I could locate. I asked, "Is it scientifically possible to imagine a
vaginal product that would kill or block HIV transmission but would not kill
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sperm?" The responses were enticing; I was frequently told that it was
attainable. It was upsetting to learn then, from the same sources, that the idea
was not being pursued.
The reasons why not could easily fill a scrapbook. "Women really aren't
at risk of HIV. We have to invest our limited resources where they count." "If a
woman wants a child, she should just stop using a condom for a while." And my
favorite: "Such a product could be counterproductive in the long run because
women would stop using condoms." This response, of course, ignores the
reality that for many woman the choice is not be between a condom and a
microbicide, but between a microbicide and nothing at all.
My initiation into the world of microbicide research has convinced me that
the scientific community is often dangerously divorced from the reality of
women's lives. I see the Partnership for Prevention consultation as a first step
toward confronting this predicament and making sure that women's voices are
heard.
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As Chris and Lori's paper details, many questions remain regarding the
reproductive biology associated with HIV transmission, such as identification of
the specific infectious elements in semen, determination of the precise cells and
tissues in the reproductive tract susceptible to infection, and the possible
association of HIV with sperm. Other questions regard the local bacteriological,
pH, and immune factors that comprise and sustain the ecology of the
reproductive tract and the range of possible preventative mechanisms. This
research, and the product development, testing, and registration of any new
biotechnology takes up to seven to ten years. Thus, development of safe and
effective microbicides will require a great deal of research effort. Testing of
potentially microbicidal compounds is in its very early stages and, hence, the
availability of new microbicidal vaginal products is still some time off -- time that
is precious in the face of the global HIV epidemic. This reality further supports
the need for close cooperation between scientists and advocates -- to expedite
the development process as much as possible, but more importantly, to
contextualize the work on new technologies so that we do not lose sight of the
parallel need for concerted attention to other strategies for women's protection.
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The Role of Women's Health Advocates in Technology Research and
Development
Amparo Claro
Coordinator
Latin American and Caribbean Women's Health Network

Having an open dialogue between scientists and women's advocates
should be the first step in the research regarding women's reproductive health,
including microbicide and contraceptive research. By involving women's groups
in all phases of the process, reproductive health research will take a fundamental
step forward and scientists, women's health advocates, and the technology
under development will greatly benefit from the new alliance.
Carmen Barroso, (Director, Population Program, MacArthur Foundation),
suggests several ways in which a scientific agenda is advanced by collaboration
with women's health advocates. She points out that advocates work to:
•

counteract conservative forces that oppose the development and delivery of
contraceptive methods;

•

gain the attention of policy makers who traditionally fail to give issues related
to demographics and women's health due notice;

•

increase the ultimate effectiveness of the range of reproductive technologies
by providing details of the complexity of women's lives affecting the
acceptability of methods; and

•

help the scientific community in creating conditions for the implementation of
high ethical standards.
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Additionally, involving women's health advocates in clinical trials benefits both
the study participants and the scientists. When researchers become allied with
women's health advocates in the health centers where clinical trials are
conducted, information about the product being tested is dispersed through local
networks and members of the community. If involved in this process, women's
health advocates would establish open and meaningful communication with the
study participants which would provide, for the scientists, more accurate and
complete reactions to the product. One way to accomplish this partnership
would be for agencies to begin a dialogue with local networks by sending project
lists to local organizations requesting input and collaboration. Additionally, a job
position for a women's health advocate could be written into the original
proposal. Taking these steps would serve to create a participatory, democratic,
and respectful approach to the development of a new technology because the
study participants and their communities would be regarded and employed as
significant contributors to the research instead of passive participants.
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Many concerns have been expressed regarding the feasibility of designing
clinical trials of microbicides that are both scientifically valid and ethically sound.
Before entering human testing, a candidate compound would go through
standard testing for toxicity in laboratory animals. With minor modification, the
typical product-development sequence for a new vaginal contraceptive could be
applied to the pursuit of new microbicidal compounds. The early evaluation of
potential products will obviously require significant attention to the possible
mutagenicity of vaginal compounds, especially those that are potentially
noncontraceptive. Following successful testing in vitro and in animal models, a
carefully selected group of potentially microbicidal compounds will be brought to
human trials. Human trials typically involve three phases prior to drug
registration: Phase I trials evaluate the safety, toxicity, and acceptability of a
product in a small number of women; Phase II trials generally involve moderate
numbers of women and are designed to establish some evidence of
effectiveness; and Phase III trials expand the safety and effectiveness testing to
large numbers of women. For a typical compound, completion of all three
phases of human clinical trials can take at least five years, but may take longer
for microbicide evaluation, given the sample size requirements and special
characteristics of study populations.
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A View from the Laboratory
Rachael Pearce-Pratt
Center for Biomedical Research
The Population Council

I viewed the meeting as an opportunity to discuss the basic science
surrounding vaginal microbicide development with women's health advocates
without oversimplifying the complex mechanisms involved in sexual transmission
of HIV. The questions that the advocates raised regarding the relevance of the
science to the "real-life situation" of heterosexual intercourse were well
appreciated and fit in with our overall goal to make our laboratory systems as
life-like as possible. Additionally, we benefited by hearing, first-hand, what were
the realities of some of the women's lives for whom this product will be
developed.
During the first session of the meeting, we discussed the idea that
scientists and women's health advocates speak different languages and thus
may not always be able to comprehend each other's approach to a new
technology like microbicides. Our initial apprehension as to whether we could
communicate as a group, however, was unfounded. In fact, the clarity and level
of honesty in putting the issues that mattered most to us on the table had the
effect of uniting all participants.
As scientists, we were surprised when the women's health advocates
acknowledged that scientific research -- especially with respect to women's
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reproductive health -- is often viewed suspiciously. Consequently, we were
eager to reassure participants that we are concerned that any microbicide, once
developed, will truly be woman-controlled and to insure this, we need women's
health advocates to inform our work by expressing the global concerns of women
about such a product. We need them to inform us about cultural practices that
might make one formulation unacceptable in a certain society or necessitate that
a microbicidal product be completely undetectable. Only by collaborating with
women's health advocates do we learn both the realities of how clinical trials are
actually implemented and that sometimes the way the design is interpreted "in
the field" generates misleading results.
Women's health advocates are invaluable intermediates between the
laboratory and the policy-making processes. We anticipate an essential relay of
information as we go forward with the development of a female-controlled
microbicide.
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The major challenge with respect to microbicide development is to design a
Phase III effectiveness trial that is both scientifically rigorous and ethically
defensible. From a scientific standpoint, the most rigorous, and therefore the
most desirable, design is a randomized controlled trial, where trial participants
are randomly assigned to receive either the compound under investigation or a
placebo. Since it would be unethical to withhold a form of HIV prevention known
to be protective, participants in a microbicide trial would also receive free
supplies of condoms and be counseled to use both the vaginal product and a
condom during each act of intercourse. Statistical techniques would be used to
determine any incremental benefit offered by the experimental compound over
condom use alone.
This type of trial design raises important ethical issues. An unfortunate reality
to be faced in conducting such a trial is that, at best, some members of the
comparison group will become infected with HIV while participating in the study.
The critical ethical question, however, is whether all study participants will benefit
from participation in the trial. Researchers have an obligation to minimize harm
and to maximize the benefits to all trial participants. In the optimal design,
therefore, all participants, including those in the control group, would benefit from
receiving condoms, reproductive health care, and intensive HIV counseling. If
the trial were performed properly the women in the control group should have a
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lower HIV seroconversion rate than women not participating in the study.
Historical controls could be used to document improved use of condoms by all
participants as a direct measure of the benefit of participating in the trial.
Attention to the ethics of clinical trial design is especially important because
those groups of women who are at greatest risk of HIV and, hence, are often
sought out by investigators for study participation (the greater the infection rate,
the smaller the required sample size) are often extremely vulnerable to
exploitation. Many of these women are sex workers. Given the economic, legal,
and violent realities of many of these women's lives one must carefully examine
the feasibility of actually obtaining informed consent, as well as the possibility of
their further exploitation if the trial is not implemented as designed.

22

Research: Empowering or Exploitative?
Liz Cameron
Empower
Chiang Mai, Thailand

Women doing sex work in brothels are often referred to as a "vulnerable
population". It is not, however, that the women themselves are "vulnerable", but
instead their working conditions leave them unprotected from exploitation and
abuse. The realities of their lives are such that they are not able to choose when
to eat, bathe, sleep, or work. They cannot choose to whom they sell sex or
where they will go when they are ill. The brothel owners make these decisions,
along with those regarding their health care, wages, hours, and methods they
use for prevention of pregnancy and STD. Sex workers are also vulnerable to
exploitation from people conducting clinical trials; again the brothel owner
decides whether the women will participate. "If we don't go for our interviews
and tests, they contact our bosses and they tell us to go," explained one woman
enrolled in a clinical trial.
The reality is that sex workers work extremely hard to support their
families under the stress of financial hardship and the threat and effects of
disease. In their limited free time, these women struggle to get education and
improve their standard of living. One woman enrolled in a pre-clinical trial says,
"Last night I didn't finish work until 4 a.m. I had to get up early to take my son to
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school. I'm exhausted and would like to go to sleep but I have to go for an
interview and test. I wish they would ask me what time is good for me." These
women do not ask the outside world to solve their problems and, to a large
extent, the rest of the global community seems content to leave these women to
struggle alone.
Thai sex workers are distressed by the influx of reproductive health
researchers from around the world. Social researchers intrude into their lives,
and sex workers wonder whether the researchers are coming with the aim to
address the needs and concerns of sex workers or to satisfy the agenda they
came with. During a workshop on the ethics of research held by Empower, one
woman asked, "Don't they have women doing sex work in other countries? Why
come here where we have no rights?"
Both the researchers and the implementation of the study design don't
meet these women's expectations. "I didn't know I would have to answer such
personal questions. I was very embarrassed." Another says, "I thought it was
important to be honest so I told him that I cannot always insist on condoms with
every customer. I expected him to talk to me about the risks. Instead he just
wrote it down, as he told me he was in a hurry to go and eat his lunch." Often
women assume participation will in some way improve the conditions of their
lives, even if explicit promises aren't made.
The medical community has been "doing research on sex workers"
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instead of joining with the sex-worker community for mutually beneficial research.
The recruiting teams come into the women's homes and bedrooms after gaining
consent to access by the brothel owners, not the women themselves. One
woman who was enrolled in a pre-clinical trial explains, "I couldn't ask any
questions or talk properly because I knew the owner was just outside and would
hear everything."
The realities of the lives of the participants determine whether a clinical
trial is ethical, regardless of how well it is intended or designed. Regardless of
informed consent, use of women who work in brothels in clinical trials is unethical
because the women themselves don't grant consent. If an organization seeks to
conduct research on a "vulnerable population", they should first take the time
truly to learn the realities of the women's lives. Doing this would take a
researcher years, but would result in more ethical studies and scientifically valid
results.
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The individual women who would participate in clinical trials will not
necessarily benefit in the near term from the development of a vaginal
microbicides. These women are at high risk of HIV infection and, in the seven to
ten years it will take to develop, test, and register a microbicidal product, many
will probably already become infected with the virus. While pursuing the long
term goal of developing new microbicidal products, public health workers must
also insist on more work to determine the safety and effectiveness of existing
products, such as over-the-counter spermicides that may have some
microbicidal activity.
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Interim Prevention Strategies: The Debate over Nonoxynol-9
Vicki Legion
Community Health Worker Training Program
City College of San Francisco/San Francisco State University

Until recently, I worked at the Vida/SIDA (Life/AIDS) prevention project in
a Puerto Rican neighborhood on the west side of Chicago. In this neighborhood,
we experience the same trends reported from around the globe. Every day we
hear women -- especially young women -- telling us loud and clear that condom
use isn't relevant to their reality: "You can keep the condoms. My man will
never go for it. Have you got anything else for me?"
The "anything else" that we have is a very slender thread: our practice of
educating women with uncooperative partners about N-9 (nonoxynol-9) for
partial protection against bacterial STDs. This lack of HIV prevention options is
especially agonizing because it often seems that women at highest risk -- such
as women in relationships with injection drug users and those who trade sex for
money, drugs, or favors -- have the least likelihood of getting cooperation from
their partners in the use of condoms.
What are we to do until a female-controlled microbicide is available?
There is evidence to suggest that the spermicide nonoxynol-9 might provide
some protection against STD, including HIV. N-9 is a biodetergent which has
been used in the United States for 40 years as the contraceptive ingredient in
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spermicidal jellies, creams, suppositories, foams, and films. A number of studies
have shown N-9 to be partially effective in preventing common STDs, such as
gonorrhea and chlamydia. Data is conflicting regarding the ability of N-9 to
protect against HIV infection. No institution, however, has launched an
aggressive research effort, nor even conducted a review of existing literature in
order to craft an interim prevention message based on the available data, some
of which is quite promising.
The result is that the prevention message for women is complete chaos:
some sources advocate spermicide use for STD prevention, stressing that STD
infection is a co-factor for HIV transmission while others send the message that
N-9 creates lesions which are also considered co-factors for transmission. In the
confusion, there is a deafening silence with respect to the critical situation facing
the millions of women who are now unable to protect themselves.
In light of the public health crisis of HIV transmission, three issues emerge
in the question of an interim message regarding N-9 use:
•

This is an emergency -- with a tidal wave of new infections bearing down on
us, an imperfect, partial solution is better than a non-option.

•

Women are able to understand a hierarchical message that is more
complicated than "condoms, condoms, condoms" and should be presented
with available data, even if it is inconclusive.

•

The debate over N-9 should be kept open and studies on its effectiveness as
a microbicide must be urgently pursued.
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The potentially microbicidal spermicide nonoxynol-9 has been the focus of
much controversy. Almost certainly, N-9 may have a lower method effectiveness
as a prevention against HIV transmission than a physical barrier provided by a
male or female condom. It may however, have the potential for higher use
effectiveness because it is female-controlled and does not necessarily require
the consent of a partner. Use effectiveness is the performance of a product in
actual use while method effectiveness measures its performance under perfect
use conditions. Regardless of its effectiveness as a microbicide, however,
health workers face another problem when presenting N-9 as a possible femalecontrolled STD prevention method. As a spermicide, it -- like condoms -prevents pregnancy.
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Practical Realities and Women's Protective Needs

Muriel J. Harris
Director
Society for Women and AIDS in Africa (Sierra Leone)

The place of a woman in the traditional African society makes her
vulnerable to HIV infection. She is socially dependent on the man she marries,
and although she contributes significantly to the income of the home, she is
economically dependent on him as well. That it is generally accepted that men
have multiple casual sexual partners also increases a woman's risk of STD and
AIDS. Her husband may take a new wife when he chooses, and if a man dies,
his wife is married to his brother.
The emphasis within traditional African culture on child-bearing makes
existing prevention strategies including condoms inapplicable to women in that
society. It is believed that a woman must produce all the children that God will
give her and a woman must prove early on in her marriage, and irrespective of
her age, that she is capable of bearing children. She must provide the
husband's family with a son as soon as possible, even if it means having multiple
pregnancies which compromise her health. The higher the number of sons, the
higher the status of the mother. The total number of children she bears will
determine her status in that community. Any use of contraceptives, then, are
concealed from her husband.
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The use of condoms is limited within the general population and this use
is often related to sex within a casual relationship. A woman who requests
condom use is often thought to have other sexual partners which can cause
considerable problems of trust. Men believe that their ejaculate must have the
potential to create a life and refuse to use condoms within their stable
relationships.
It is clear, then, that a non-contraceptive vaginal microbicide that a woman
could use without the consent of her partner is urgently needed in Africa.
Available STD prevention methods including the condom or even potentially
microbicidal products like N-9, prevent pregnancy and therefore are
unacceptable to a woman whose status is wholly dependent on the number of
children she produces. The woman's low status in traditional African society -which compounds her vulnerability to STD -- needs also to be addressed in frank
and non-judgmental terms, but a non-contraceptive microbicide may save her life
long before societal change is realized.
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It is evident from above that an improved STD/AIDS prevention strategy
must address both the longterm or strategic gender needs of women, i.e. efforts
must challenge and alter the current power imbalances between women and
men, as well as meet the immediate, practical need for woman-controlled
technology. Such a strategy must emphasize the fact that all sexually active
people are at risk of STD/AIDS. Without such efforts, microbicides are likely to
be perceived only as a "technological fix" that at best by-passes, and at worst
reinforces, gender power imbalances. In fact, behavioral and attitudinal factors
make a "technological fix" for the STD/AIDS epidemic virtually impossible.
It is unlikely that, after a vaginal microbicide is developed, it will prove
100% effective in preventing the transmission of STD/HIV. It is more likely that a
microbicide will offer limited protection against HIV and other STDs, and ideally
would be used in addition to condoms when possible. This latter reality, among
others, such as the safety and cost of microbicides, will be of tremendous
importance when the time comes to consider introducing this new technology,
and underscores the need for full participation of women's health advocates from
the start.
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No Quick Fix: Integrating Microbicides into an Overall AIDS Prevention
Strategy
Nicolien Wieringa
Women's Health Action Foundation
Amsterdam, The Netherlands

The problem of women at high risk of STDs and AIDS is the result of
many interrelated factors. These include multiple sexual partners, lack of
knowledge about STDs, lack of condoms, lack of adequate medical services,
inequity in power relationships between women and men, having other STDs,
and the high prevalence of HIV in a community. Because of the complexity of
these factors an integrated approach is needed to adequately address the
situation of women at high risk for HIV. Looking in further detail at the
influences that cause women to be at high risk for HIV transmission through
heterosexual contacts, the following factors can be identified:
•

Disease related factors at the individual and community level; high
prevalence of HIV infection and other sexually transmitted diseases (STDs).

•

Factors related to the political and socio-cultural context in countries;
multiple partners and sexual habits causing high risk of vaginal lesions;
inequality in power relations between women and men.

•

Factors related to the quality of the health care system: lack of medical
care in the case of STDs, lack of knowledge about HIV transmission and
preventive measures, lack of condom availability.
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These problems exist in developed and developing countries, although
they appear in varying intensity and balance. The aim is to develop health
policies based on a framework to control STDs and HIV wherein user's
perspectives and needs are central.
Not only is a concomitant STD a factor leading to an increased risk of HIV
transmission, it is a marker of a woman's risk and social vulnerability. This reality
suggests that it is just not enough to develop a technological fix to prevent HIV.
With the present high numbers of women and men already infected with STDs,
major efforts are needed to give adequate care and treatment, especially in a
time when economic constraints present a difficult challenge. The following
issues should be included in a comprehensive strategy:
1. Education, to encourage women to seek medical consultation when
they experience vaginal complaints and to teach them the relationship
between their complaints and the sexual transmission of diseases that
cause them; to empower women to take care of their bodies.
2. Treatment of STDs with antibiotics in order to reduce the number of
people infected.
3. Counselling and consultation to achieve treatment of sexual partners in
case of STDs and to improve the acceptance of preventive measures.
4. Preventive measures, providing condoms, other barrier methods and
safe and effective microbicides. It is vital that condoms are not only
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promoted through AIDS programs, but also in family planning services in
order to make the connection between sexual behavior and contraception,
STDs, personal care, and wellbeing.
5. Development of a medical infrastructure to provide adequate care for
diagnosis and treatment of STDs. Ideally, this type of care needs to be
integrated with reproductive health services, including access to different
contraceptive methods and abortion services, along with services to
prevent and treat infertility. Treatment, counselling and prevention of
STDs are necessary elements of easily accessible medical care.
Developing and introducing microbicides needs to go hand in hand with
developing policies to implement better health care services directed
towards controlling STDs.

I'd like to make one final point. There is a continuing need to focus on the
use of condoms for the prevention of HIV, as at this moment it is unknown
whether a microbicide will ever be more effective than a condom of good quality
in preventing the sexual transmission of HIV. The use of condoms is still, and
may always be, the best prevention option for women to whom they are
accessible and practical.
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Reflections and Hopes
Christopher Elias, The Population Council
Adrienne Germain, International Women's Health Coalition

We began discussing our plans for a consultation between women's health
advocates and Population Council scientists on the topic of microbicides almost
a year before our May 1994 meeting. Our thoughts were informed by the various
meetings and consultations being held around the world in preparation for the
Fourth International Conference on Population and Development in Cairo. We
noted with some trepidation the tensions that have developed within the
population field -- tensions that have often erupted into complete division and
been brought into sharp focus by issues related to technology. Who decides
what technology is developed? By whom and for whom? With what motive and
with what understanding of the realities of poverty, injustice, and exploitation?
We also noted the highly politicized world of AIDS research and wondered about
the potential complexity of the process we were contemplating.
Within this stormy background, however, we perceived the opportunity to
pursue a new model of consultation -- indeed partnership -- around the possibility
of developing safe and effective microbicides. Here was a technology that could
potentially meet the demands of women for a method of STD protection within
their personal control. The scientists involved with microbicides development at
the Population Council -- a leading public-sector reproductive health technology
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development organization -- had achieved enough internal commitment and
external resources to begin a small, but promising program of product
development. It was still early in the technology development process and these
scientists were open to exploring a meaningful dialogue with women's health
advocates. If successful, we might not just expedite and improve the relevance
and ethical standards of microbicide research, but also identify a model for
discussion concerning the development of more contentious technologies.
We discussed the need for enough time to overcome the inherent distrust that
participants might feel and to review the full range of issues and decided on a
two week consultation. At first some wondered how we would fill the time. What
if we ran out of things to say on the first day? As is evident from the preceding
essays, this did not happen. Indeed, we left feeling some issues had not
received the attention they deserved and agreed to meet again in the fall.
Through the course of eight long days we exchanged a great amount of
information. We also began the process of seeing into each other's worlds, of
understanding the shape of our respective discourses. Language revealed itself
as an important element of our consultation. What do we mean when we say
"acceptability" or "vulnerable population" or "monitoring"? The words we use whether in advocacy or science - sometimes reveal the divisive assumptions that
have polarized the fields of both population and AIDS.
And the words represent realities that are even more vastly different. The
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real world of the product development and registration process, with its scientific
uncertainties, regulatory and liability issues, and requirements for demonstration
of safety and effectiveness greatly influences what counts as "progress" and
"success" in science. Similarly, hearing about the day to day realities of life as a
brothel-based sex worker and the problematic implementation of well-designed
clinical trials gave a new texture to the challenge of identifying a "vulnerable
population" appropriate for microbicide efficacy testing.
In summarizing our eight day consultation, it is important to not over-claim our
success. We have opened the doors to an effective partnership. In terms of the
goals of the meeting, we have made considerable progress in regard to three of
the five. As reflected in the earlier essays of this report, we have fostered
considerable sensitivity and insight among scientists regarding the realities of
women's lives, we have increased the ability of women to serve as effective
advocates by increasing access to accurate scientific information, and we have
furthered the dialogue between women's health advocates, scientists, and
program planners on issues that affect women's sexual and reproductive health.
All of these activities need to continue and to form the basis for an on-going
exchange and dialogue. Our remaining two goals -- to ensure that the
Population Council's current commitment to microbicide development results in
the availability of vaginal products that are safe, effective, and meet women's
needs and to develop a model for future reproductive health technology
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development that engages women as active partners in all aspects of the
product development process -- are longer term aspirations that will require that
we go beyond simply meeting and exchanging information and viewpoints. As
Amparo Claro emphasized during our meeting, a true partnership will require a
more participatory approach. To this end the group is considering several
possible areas of collaboration - as discussed by Lori Heise in the following
section.
In summary, the outcome of our consultative process is very hopeful. It has
documented the benefits of a concentrated exchange of ideas and outlines the
possibility of a truly fruitful partnership for the future. In the face of the rapidly
expanding global epidemic of sexually transmitted infection and AIDS, the
importance and the urgency of this alliance cannot be overstated.
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Furthering the Partnership
Lori Heise
The Pacific Institute for Women's Health

In the fall of 1994, the women's health advocates plan to meet again to
further consolidate a vision for long term collaboration on microbicide
development and testing. The group has decided to seek an identity separate
from the Population Council, but remains committed to working with the
Population Council scientists and staff to provide input at each step of the
microbicide testing and development process. Henceforth, the Pacific Institute
for Women's Health in Washington, DC will serve as the secretariat for the group
which has renamed itself the "Engendering Microbicide Project."
The goal of the Engendering Microbicide Project is to serve as a technical
resource and advocacy group to help ensure that women's needs and
perspectives are included at every phase of the microbicide development
process. A major focus of the group will be interacting with the Population
Council's research and development process, although the group hopes to have
an impact on the wider research and funding community. Ultimately, the project
hopes to forge a new model for reproductive health technology development that
engages women as active partners in all phases of the development process.
As one of its first activities, the Engendering Microbicide group intends to
hold a two-day discussion at its autumn meeting on product "acceptability" from
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a feminist perspective. Traditionally, there has been very little acceptability
research done to inform the development of new contraceptive technologies.
What do women want? What criteria are most important to them? What factors
will determine whether they will use a product? The research that has been
done has generally focused more narrowly on women's formulation preference
(e.g.: Do women prefer a cream to a foam?) At the November meeting,
women's health advocates will explore the wider set of parameters that affect
women's perceptions of "acceptability" including the side effects of new
technologies, the preferences of one's partner, and whether a method can be
hidden. The group hopes to develop several proposals for research undertaken
by and for women, on microbicide acceptability.
The group is also planning a major seminar for Spring 1995 to discuss
issues surrounding the design and implementation of Phase III trials. The idea is
to broaden the current dialogue on trial design and implementation to include
voices not normally heard from on this issue: women's health advocates, trial
participants, feminist ethicists, human rights workers, and policy makers. By
bringing clinical investigators, researchers, and women's health advocates
together, the group hopes to forge a new vision of how trials could and should be
run. In addition to developing generic principles to guide trial design,
implementation, and monitoring, the Engendering Microbicide project hopes to
generate concrete suggestions that can be incorporated into the design of Phase
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II and III testing of possible microbicides.
The group will continue to meet twice a year to advance its own and
others' thinking on microbicide development and testing. The key will be to stay
one step ahead of the technology development process so that the
"Engendering Microbicides" network can continue to contribute its expertise and
insights into the design and testing of a new vaginal microbicide.
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Recommendations of the Women's Health Advocates
Presented to the Senior Officers
and President of the Population Council
1.
We endorse the process of consultation with women's health
advocates in the course of microbicide development. We feel that a
sustained commitment to this type of partnership would have a variety of
positive benefits for the Population Council and the field of contraceptive
technology development in general, including:
a)
building greater understanding and mutual respect among
women's health advocates and the Population Council staff and
scientists,
b)
helping to ensure that whatever microbicidal product is
developed truly meets women's needs and will be widely accepted
and used, and
c)
helping to mobilize sustained support outside of the Council
for greater financial investment in microbicide research.
2.
As a leader in the field of reproductive technology and as the best
public sector agency positioned to do so, we encourage the Population
Council to pursue whatever means necessary to expand current
investment in microbicide research. We understand that the Population
Council is laboring under staff and space limitations but we feel the
urgency of women's need for microbicidal products warrants concentrated
effort to overcome these barriers. We are greatly encouraged, indeed
excited, about the possibilities presented by sulphated polymers, but feel
it is essential that the Council (and others) accelerate the search for other
potentially microbicidal compounds.
3.
We urge the International Committee on Contraceptive Research
(ICCR) to expand its membership to include a female investigator with
special training and expertise in gender issues. Likewise, we encourage
the ICCR to invite selected women's health advocates (as it currently
invites funders and other outside representatives) to participate in portions
of the ICCR meetings. In addition to facilitating a mutual exchange of
ideas, such representation would help ensure that women's needs and
perspectives are raised early in the technology development process.
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4.
Beginning now, the Population Council should systemize
consultation with this group (and other women's health advocates as
appropriate) at each phase of the microbicide development process. This
would include periodic updates on the progress of the science,
consultation on the selection of research sites and the design of clinical
trials, and an opportunity to review and comment on all protocols prior to
implementation. The Council should consider expanding this type of
consultation process to other reproductive technologies now under
development.
5.
We strongly believe that the development of topical microbicides
for intravaginal use should always be presented in the context of an
overall program to reduce women's risk of contracting HIV and other
STDs. A new technology is simply one of many complex activities that
must be pursued to empower women and reduce their risk. Given the
tendency of individuals and institutions to pursue "technological fixes" at
the expense of more fundamental social change, it is essential that the
Population Council, in both its public statements and internal workplans
constantly contextualize microbicide development within a broader
program of STD/HIV prevention. We recognize that the Ebert Program
represents a firm commitment to this type of multidimensional approach,
but we are concerned that the current staffing level may be inadequate to
accomplish the objectives laid out in the new mission and mandate
regarding STD/HIV prevention and control, especially given Dr. Elias's
planned departure from the New York office. We encourage the Council
to review its current staffing levels in light of its newly articulated
commitment to a broader reproductive health mission.
6.
We are encouraged by the Population Council's emerging
commitment to institutionalize monitoring of the informed consent process
in all of its clinical trials. This represents an important shift toward greater
concern with how trials are actually implemented in addition to the
research community's long-standing commitment to scientifically and
ethically defensible trial designs. Because this is such a pathbreaking
area of work, we would suggest strong collaboration between the
programs division and CBR in developing the process by which such
monitoring can be achieved. We encourage a systematic process of
action research and reflection to develop the system and principles upon
which to base this monitoring. Important issues remain outstanding:
Should the monitors be outside consultants or Council staff? What criteria
should be used for picking monitors? Who should such monitors consult
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for information in addition to the trial participants themselves? How
should such monitors be trained and evaluated? To discover the best
methodology for doing such work, the Council should consider sending
multidisciplinary teams to several sites to perform monitoring and have
them reconvene to share experiences and techniques. Based on these
experiences, the Population Council should develop a detailed training
manual and list of recommendations for future monitors. The Council
should remain open to the possibility that different types of monitors with
different scopes of work may be necessary depending on the type of trial
and the vulnerability of the trial participants.
7.
We are encouraged by the emerging shift in health-related
research and care towards including representatives from the
communities affected (patients, trial participants, etc.) in the design of
research studies and in agenda setting. We recommend that the
Population Council explore ways to institutionalize such a commitment in
the organization of its work.
8.
As a member of the interagency microbicide task force, the
Population Council should lobby to add two woman's health advocates as
standing members of the committee. This will facilitate the integration of
women's perspectives into the research agendas and methodologies of
other institutions pursuing microbicide research.
9.
We suggest that the Population Council organize activities at the
upcoming Cairo ICPD conference to lend prominence to the development
of new female-controlled barrier methods within an overall program of
STD prevention and control.
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AGENDA
Tuesday, May 3
The Population Council
9th Floor
1 Dag Hammarskjold Plaza
Introductions
8:30

Coffee and breads available

9:00 - 10:30

Welcome and Background
(Christopher Elias, Adrienne Germain, Lori Heise)
Brief Introductions

10:30 - 10:45

Coffee Break

10:45 - 11:45

Substantive Overview of the Next 10 Days
(Christa Coggins)
Review of Draft Objectives for Meeting
Logistics/Housekeeping (Jennifer Grant)

11:45 - 12:30

Hopes and Concerns for this Process

12:30 - 1:30

Lunch

1:30 - 3:30

Personal Stories (Who are we? What brought us to this work?)

3:30 - 5:00

Discussion of Additional Meetings/
Information Sessions to be Scheduled
Group Consensus on Meeting Objectives

Wednesday, May 4
Meeting With Wider Population Council Community
Beverly Winikoff, Chairperson
8:30

Coffee available

9:00 - 9:15

Welcome (Beverly Winikoff)
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9:15 - 10:15

Integrating Women's Voices into Technology
Development: A Bit of History
(Adrienne Germain)
Practical Realities and Women's Protection Needs in Africa
(Muriel Harris)
Discussion

10:15 - 12:15

The Science of Microbicide Development (David Phillips, Rachael
Pearce-Pratt, Vanaja Zacharopoulos, Center for Biomedical
Research, The Population Council)
Discussion

12:15 - 1:15

Lunch

1:15 - 2:45

Clinical Trial Design: Ethics and Science
(Lori Heise)
Research Among Vulnerable Populations: A View from the
Field (Liz Cameron)
Discussion

2:45 - 4:15

Challenges of Microbicide Development
(Christopher Elias)
No Quick Fix: The Role of Technology in an Overall AIDS
Prevention Strategy
(Nicolein Wieringa, Women's Health Action Foundation)

4:15 - 5:00

Wine and Cheese Reception
Hosted by Beverly Winikoff and the Ebert Program
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Thursday, May 5
Meeting with staff from the CBR Laboratories
8:30

Coffee available

9:30 - 10:45

Introductions
Discussion of Outstanding Microbicide Issues
Issues of Formulation (Esther Adebayo-Olojo)
Proposed Acceptability Studies (Christa Coggins)
Prevention of Other STDs (Franca Zaretzky)

10:45

Coffee break

11:00 - 12:15

Overview of the Population Council's Contraceptive
Development Program (Rosemarie Thau, Director
of Contraceptive Development)
This will be an opportunity for participants to raise
questions/issues regarding other technologies such as contraceptive
vaccines, NORPLANT®, etc.

12:15 - 2:00

Discussion of previous presentation over Lunch

2:00 - 5:00

Continued discussion of PC Contraceptive Development
Discussion of acceptability protocol
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Friday, May 6

9:00 - 10:30

Review of Research on the Efficacy of Nonoxynol-9
for STD/HIV Prevention
(Erica Golllub)
Discussion

10:30 - 10:45

Coffee break

10:45 - 12:15

Policymaking in the Face of Uncertainty: New York State's
Hierarchy of Protection Options for Women (Mike Rampolla)
Discussion of Nonoxynol-9 Policy Options

12:30 - 2:00

Luncheon with local women's health activists
(Diana Hartel and guests)

2:00 - 3:00

Discussion of the Female Condom (Erica Gollub) Findings from
Recent Acceptability Studies

3:00 - 5:00

Further discussion of female condom, N-9 studies
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Monday, May 9th
Washington, DC
8:15

Meet in Hotel Lobby

9:00 - 12:00

Briefing on the Activities of Other Actors Involved in HIV/STD
Prevention Technologies

9:00 - 9:45

The work of the National Institute of Allergy and Infectious
Disease (NIAID) (Penelope Hitchcock)

9:45 - 10:30

The work of the National Institute of Child Health and Human
Development (NICHD)

10:30 - 11:15

The work of the Contraceptive Research and Development
Program (CONRAD) (Henry Gabelnick)

11:15 - 12:00

Lunch and discussion of morning's presentations

12:00 - 1:15

Briefing on current and future microbicide research by Family
Health International, (Paul Feldblum)

1:30 - 3:30

An Open Discussion with USAID staff (Liz McGuire, Jeff Spieler,
and colleagues)
This will be an opportunity for participants to ask questions and
exchange views with high-level AID decision makers regarding
family planning policy and programs, contraceptive research, HIV
prevention policy, etc

4:00 - 5:00

The Regulatory Process - An informal discussion with staff from
the U.S. Food and Drug Administration (FDA)

7:00

Dinner at the home of Lori Heise
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Tuesday, May 10th
The Politics of Women and HIV
8:45

Meet in Hotel Lobby

9:30

Meeting with Representative Constance Morella (R-MD), sponsor
of legislation earmarking money for microbicide research

10:30

Strategy Session with staffers of the Congressional Women's
Caucus

11:30 - 12:45

Lunch/Center for Women's Policy Studies
(Informal discussion with local advocates on the politics of
Women and HIV in the U.S.)

1:00 - 4:00

Meeting with "The Microbicide Advocacy Project," a coalition of
U.S. advocates working to build support for microbicide research

5:30 - 6:30

Fly to New York on the Delta Shuttle

7:30 - 9:00

Reception at the home of Mrs. Margaret Catley-Carlson, President
of the Population Council

53

Wednesday, May 11
Presentation of Recommendations to Senior Population Council Management
8:00 - 8:30

Breakfast - Ninth Floor Conference Room, The Population Council

8:30 - 9:45

Presentation of by Women's Health Advocates to Senior Officers
of the Population Council
(Outside funders and policymakers present)

9:45 - 10:00

Coffee break

10:00 - 11:00

Continued Discussion

11:00

Senior Officers depart

11:00 - 12:30

Further Discussion and Strategy Session with Remaining
Participants

12:30 - 1:30

Break for Lunch

2:00 - 5:00

Discussion of future steps
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Thursday, May 12
Strategic Planning for Future of Project
Evaluation of Process

8:30

Coffee Available

9:00 - 12:30

Discussion of Possible Future Activities of Group
Regional Activities
Future International Meetings
Resource Needs
Developing a Communications Plan

12:30 - 1:30

Lunch

1:30 - 2:30

Evaluation of Process to Date/Recommendations for Future

2:30 - 3:30

Developing Detailed Plans of Action
(for inclusion in a Funding Proposal to the MacArthur Foundation)

3:30 - 5:00

Getting the Word Out: Discussion of ways to mobilize our wider
constituencies
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